Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bintrafusp Alfa + Chemo/RT in Cervical Cancer
NCT04551950Phase 1Completed
- Sponsor
- EMD Serono
- Start
- Oct 2020
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors, Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 1, open-label trial of bintrafusp alfa in Cervical Cancer (CC) (3 arms), sponsored by EMD Serono. Primary endpoints: Number of Participants With Dose-Limiting Toxicities up to 4 weeks and Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) up to 20 months. Started Oct 2020; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04551950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551950.